HIV product sales growth driven by Biktarvy and Descovy
HIV product sales rose 12% in Q2 FY2026, with Biktarvy up 7% and Descovy up 48%, primarily due to higher demand and average realized prices.
GILEAD SCIENCES, INC. is expected to release its Q3 2026 10-Q filing on October 28, 2026. Last quarter: Gilead reported a net loss of $10.5 billion in Q2 FY2026 due to $12.9 billion in one-time charges, overshadowing 10% revenue growth from HIV and oncology products.
EPS Estimate
$2.27
Revenue Estimate
$7.93B
Analyst consensus from Finnhub and Financial Modeling Prep. Actual results posted within minutes of the SEC filing on the GILD page.
Drawn from management commentary in the Q2 2026 10-Q:
HIV product sales rose 12% in Q2 FY2026, with Biktarvy up 7% and Descovy up 48%, primarily due to higher demand and average realized prices.
Acquired IPR&D expenses totaled $11.2 billion, mainly from the acquisitions of Arcellx ($7.0B), Tubulis ($3.1B), and Ouro Medicines ($1.0B net).
A $1.75 billion impairment was recorded for the Trodelvy non-small cell lung cancer (NSCLC) IPR&D asset following discontinuation of the Phase 3 EVOKE-03 study.
Revenue
$7.8B
+10.18% YoY
EPS (Diluted)
-$8.45
-641.67% YoY
Operating Income
-$10.39B
-520.13% YoY
Add GILD to your watchlist to get the AI analysis in your inbox within minutes of the 10-Q filing.